Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial

Table 5 The mean and standard deviation of the primary variable before and after intervention in type 2 diabetes patients

		Vitamin D (N = 42)	Placebo (N = 43)	crude P-value^*	Adjusted P-value^***
VitaminD (ng/ml)	Baseline	17.24 (7.83)	17.56 (7.82)	0.853	< 0.001
	After intervention	38.86 (10.76)	14.79 (7.08)	< 0.001
	P-value^**	< 0.001	< 0.001
HbA1c (%)	Baseline	7.51 (0.87)	7.15 (1.12)	0.103	< 0.001
	After intervention	6.76 (0.98)	7.21 (1.11)	0.051
	P-value^**	< 0.001	0.657
SIRT1 (ng/ml)	Baseline	24.94 (4.38)	25.57 (3.37)	0.455	< 0.001
	After intervention	27.90 (5.58)	23.40 (3.88)	< 0.001
	P-value^**	< 0.001	< 0.001
Irisin (ng/ml)	Baseline	18.15 (5.96)	20.13 (7.17)	0.171
	After intervention	21.99 (5.93)	14.98 (2.76)	< 0.001	< 0.001
	P-value^**	< 0.001	< 0.001		< 0.001
HOMA-IR (N)	Baseline	5.36 (3.23)	5.83 (3.09)	0.499	0.421
	After intervention	6.44 (3.73)	7.39 (4.58)	0.295
	P-value^**	0.006	0.003
QUICKI (N)	Baseline	0.76 (0.08)	0.73 (0.06)	0.149	0.645
	After intervention	0.73 (0.07)	0.71 (0.07)	0.217
	P-value^**	0.005	0.003

ISSN: 2731-4553